Novel and Engineered Type II CRISPR Systems from Uncultivated Microbes with Broad Genome Editing Capability
The CRISPR Journal · 01.06.2023 · 6 (3) · 261-277
DOI: 10.1089/crispr.2022.0090 ↗Kurz gefasst
Fachartikel in der Zeitschrift The CRISPR Journal, online erschienen am 01.06.2023. Verfasst von Lisa M Alexander und 20 weiteren Autor:innen. Beteiligte Einrichtung: Metagenomi, Inc., Discovery, Emeryville, California, USA. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS.
Abstract (Originalsprache)
Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 nucleases have been extensively used in biotechnology and therapeutics. However, many applications are not possible owing to the size, targetability, and potential off-target effects associated with currently known systems. In this study, we identified thousands of CRISPR type II effectors by mining an extensive, genome-resolved metagenomics database encompassing hundreds of thousands of microbial genomes. We developed a high-throughput pipeline that enabled us to predict tracrRNA sequences, to design single guide RNAs, and to demonstrate nuclease activity in vitro for 41 newly described subgroups. Active systems represent an extensive diversity of protein sequences and guide RNA structures and require diverse protospacer adjacent motifs (PAMs) that collectively expand the known targeting capability of current systems. Several nucleases showed activity levels comparable to or significantly higher than SpCas9, despite being smaller in size. In addition, top systems exhibited low levels of off-target editing in mammalian cells, and PAM-interacting domain engineered chimeras further expanded their targetability. These newly discovered nucleases are attractive enzymes for translation into many applications, including therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Metagenomi, Inc., Discovery, Emeryville, California, USA.
- Bayer AG, Research & Development, Pharmaceuticals, Leverkusen, Germany.
- Metagenomi Inc., Pre-clinical, Emeryville, California, USA.
ORCID-Profile: Lisa M Alexander, Rebecca C Lamothe, Christopher T Brown
Förderung
- NIH HHS
Zitieren
APA
Alexander, L. M., Aliaga Goltsman, D. S., Liu, J., Lin, J. L., Temoche-Diaz, M. M., Laperriere, S. M., Neerincx, A., Bednarski, C., Knyphausen, P., Cohnen, A., Albers, J., Gonzalez-Osorio, L., Fregoso Ocampo, R., Oki, J., Devoto, A. E., Castelle, C. J., Lamothe, R. C., Cost, G. J., Butterfield, C. N., …, & Brown, C. T. (2023). Novel and Engineered Type II CRISPR Systems from Uncultivated Microbes with Broad Genome Editing Capability. The CRISPR Journal, 6(3), 261-277. https://doi.org/10.1089/crispr.2022.0090
Vancouver
Alexander LM, Aliaga Goltsman DS, Liu J, Lin JL, Temoche-Diaz MM, Laperriere SM, et al. Novel and Engineered Type II CRISPR Systems from Uncultivated Microbes with Broad Genome Editing Capability. The CRISPR Journal. 2023;6(3):261-277. doi:10.1089/crispr.2022.0090
BibTeX
@article{Alexander2023,
author = {Alexander, Lisa M and Aliaga Goltsman, Daniela S and Liu, Jason and Lin, Jyun-Liang and Temoche-Diaz, Morayma M and Laperriere, Sarah M and Neerincx, Andreas and Bednarski, Christien and Knyphausen, Philipp and Cohnen, Andre and Albers, Justine and Gonzalez-Osorio, Liliana and Fregoso Ocampo, Rodrigo and Oki, Jennifer and Devoto, Audra E and Castelle, Cindy J and Lamothe, Rebecca C and Cost, Gregory J and Butterfield, Cristina N and Thomas, Brian C and Brown, Christopher T},
title = {Novel and Engineered Type II CRISPR Systems from Uncultivated Microbes with Broad Genome Editing Capability},
journal = {The CRISPR Journal},
year = {2023},
volume = {6},
number = {3},
pages = {261--277},
doi = {10.1089/crispr.2022.0090}
}
EUVIMED